Table 5.
Distribution of demographics and comorbidities over time for patients receiving CRT
| Overall comparisons between groups | |||||
|---|---|---|---|---|---|
| 2000 – 2005 (N=24) |
2006 – 2011 (N=41) |
2012 – 2018 (N=104) |
Total (N=169) |
p value⁑ | |
| Age | 0.35 | ||||
| Mean (SD) | 69.0 (16.4) | 67.8 (12.8) | 70.1 (14.2) | 69.4 (14.1) | |
| Range | (26.0–91.0) | (37.0–90.0) | (18.0–93.0) | (18.0–93.0) | |
| Sex | 0.77 | ||||
| Female | 7 (29.2%) | 9 (22.0%) | 28 (26.9%) | 44 (26.0%) | |
| Male | 17 (70.8%) | 32 (78.0%) | 76 (73.1%) | 125 (74.0%) | |
| Atrial fibrillation | 17 (70.8%) | 28 (68.3%) | 79 (76.0%) | 124 (73.4%) | 0.61 |
| Coronary artery disease | 22 (91.7%) | 33 (80.5%) | 92 (88.5%) | 147 (87.0%) | 0.33 |
| Congestive heart failure | 24 (100.0%) | 33 (80.5%) | 98 (94.2%) | 155 (91.7%) | 0.007 |
| Chronic kidney disease | 17 (70.8%) | 24 (58.5%) | 57 (54.8%) | 98 (58.0%) | 0.36 |
| Chronic obstructive pulmonary disease | 12 (50.0%) | 15 (36.6%) | 49 (47.1%) | 76 (45.0%) | 0.45 |
| Diabetes | 17 (70.8%) | 25 (61.0%) | 76 (73.1%) | 118 (69.8%) | 0.36 |
| Hypertension | 21 (87.5%) | 32 (78.0%) | 94 (90.4%) | 147 (87.0%) | 0.14 |
| Obesity | 10 (41.7%) | 20 (48.8%) | 71 (68.3%) | 101 (59.8%) | 0.015 |
| Valvular heart disease | 3 (12.5%) | 10 (24.4%) | 20 (19.2%) | 33 (19.5%) | 0.50 |
| Hyperlipidemia | 21 (87.5%) | 32 (78.0%) | 97 (93.3%) | 150 (88.8%) | 0.03 |
| Any_cancer* | 9 (37.5%) | 7 (17.1%) | 21 (20.2%) | 37 (21.9%) | 0.13 |
| Charlson comorbidity index | |||||
| Mean (SD) | 3.3 (2.2) | 3.0 (2.0) | 2.7 (1.7) | 0.31 | |
*
including lymphoma, leukemia and metastatic solid organ tumors
⁑
p-value compares demographics over time groups